The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 224 participants.

Also called NCT03614260

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 224 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03614260
Main results
  • Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial JAMA, 2023-02-28 DOI, PubMed 36853250, PMC9975904 PubMed links an erratum for this paper. Erratum: PMID 37314287 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, France, Germany, Ireland, Netherlands, Switzerland, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03614260. Randomized; double masking; primary purpose treatment. Start 2018-12-14 (actual); primary completion 2022-12-21 (actual). Results posted on 2026-09-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
Acronym
RADIANCE-II
Condition
Hypertension
Condition
Vascular Diseases
Condition
Cardiovascular Diseases
Intervention (Device)
Paradise Renal Denervation System
Intervention (Procedure)
Renal Angiogram
Lead sponsor
ReCor Medical, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03614260
Content hash
5efdd4fa1fc2e79a0487249d3ee0e925fc46f2c46d5f0343d58b68ed2a8cdc72